Shares of Pharming Group N.V. (PHAR) surged 10.60% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results, raised full-year guidance, and positive developments in its product pipeline. The biotech firm, which specializes in rare disease treatments, demonstrated significant growth in its commercial portfolio and advancing pipeline.

Pharming's second-quarter earnings per share came in at $0.06, substantially outperforming the analyst consensus estimate of -$0.03. This marks a remarkable improvement from the $0.02 loss per share reported in the same quarter last year. Total revenues for the quarter reached $93.2 million, up 26% year-over-year and exceeding analyst expectations of $82.63 million. The company's flagship product, RUCONEST®, saw a 28% increase in revenue to $80.4 million, while Joenja® revenue grew 15% to $12.8 million.

Buoyed by the strong performance, Pharming raised its full-year 2025 revenue guidance to a range of $335 million to $350 million, up from the previous guidance of $325 million to $340 million. The company also reported progress in its pipeline, including advancements in leniolisib for additional primary immunodeficiencies and KL1333 for mitochondrial diseases. Notably, a recent study published in the journal Cell suggested a potentially significant expansion of the addressable patient population for Joenja®, further boosting the drug's long-term commercial prospects.

CEO Fabrice Chouraqui expressed confidence in the company's long-term strategy, citing the strength of their commercial portfolio and advancing pipeline targeting significant, underserved markets. The market's positive reaction reflects growing investor confidence in Pharming's ability to deliver on its growth objectives in the rare disease space.